Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 133Breast Neoplasms 95Colorectal Neoplasms 65Carcinoma, Hepatocellular 57Squamous Cell Carcinoma of Head and Neck 48Stomach Neoplasms 46Lung Neoplasms 44Triple Negative Breast Neoplasms 43Prostatic Neoplasms 43Leukemia, Myeloid, Acute 43Small Cell Lung Carcinoma 41Uterine Cervical Neoplasms 40Rectal Neoplasms 37Neoplasms 31Pancreatic Neoplasms 30Recurrence 29Neoplasm Metastasis 29Esophageal Squamous Cell Carcinoma 25Esophageal Neoplasms 24Ovarian Neoplasms 23Nasopharyngeal Carcinoma 21Carcinoma, Renal Cell 21Brain Neoplasms 21Melanoma 20Lymphoma, Large B-Cell, Diffuse 20Colonic Neoplasms 20Endometrial Neoplasms 19Multiple Myeloma 18Head and Neck Neoplasms 18Biliary Tract Neoplasms 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × Urogenital Diseases × Clear all
NCT07457164 2026-03-12

A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer

Antev Ltd.

Phase 2 Not yet recruiting
40 enrolled
Genitourinary

Urogenital Diseases, Prostatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡